Myopic Choroidal Neovascularisation
Conditions
Brief summary
This is a multi centre, single arm, prospective observational phase 4 study in naive or pretreated patients with myopic neovascularization. The patients will be treated with intravitreal injections of Aflibercept following a real life protocol. This sudy aims to evaluate the visual acuity during a 36 months period of time.
Interventions
OTHERAFLIBERCEPT
Patients will be treated following a real life protocol and according to the French recommendation
Sponsors
Poitiers University Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No
Inclusion criteria
* Man or woman aged 18 years and more under reliable method of contraception for woman with childbearing potenteial (hormonal or any intrauterine devices). * High myopy defined by refractive error ≤ -6 D or History of high myopia among pseudophakic patient or patient treated with refractive surgery * Patient with active CNVm * • Patients naïve or Patients pretreated with previous history of laser photocoagulation or PDT or by other anti-VEGF treatments who did not receive injection since the last 3 month * with OCT or angiography examination
Exclusion criteria
* Treatment with an anti VEGF administrated by intravitreal injection within 1 months prior to baseline in the study eye. * Treatment with PDT or laser administrated within 6 months prior to baseline in the study eye. * History of vitrectomy in the study eye * History of any other retinal disease * VA less than 20/250
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| visual acuity measurement | 6, 12, 24 and 36 months | Efficacy measurement will be performed by mean change of ETDRS for Best Corrected Visual Acuity evaluation (ETDRS score at 4 meters) from baseline to 6, 12, 24 and 36 month after initation of treatment by aflibercept |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| visual acuity measurement after other treatment such as laser, pdt visudyneor other IVT treatment | 6, 12, 24 and 36 months | Efficacy measurement will be evaluated by mean change of ETDRS for Best corrected visual Acuity evaluation after initation of treatment by aflibercept after switch from other treatment such as laser, visudyne PDT or other IVT treatment, after 6, 12, 24 and 36 months of treatment with Eylea |
| pourcentage of patients who gain more than or equal of 15 letters | 6,12,24 and 36 months | Efficacy measurement will be evaluated by pourcentage of patients who gain more than or equal of 15 letters at 6, 12, 24 and 36 months after initiation of treatment with aflibercept within naïve or after switch from other treatment such as laser, visudyne PDT or other IVT treatment, |
| visual acuity measurement in naive patient | 12, 24 and 36 months | Efficacy measurement will be performed by mean change of ETDRS for Best corrected visual acuity evaluation from baseline to month 12, 24 and 36 after initation of treatment by aflibercept in naïve patients |
| Anatomics parameters by color photographs | 6, 12, 24 and 36 months | On color retinal photographs: Presence of retinal hemorrhage Presence of macular atrophy or lacquer cracks, |
| Anatomic parameters by fluoresceine angiography or angiography oct | 6, 12, 24 and 36 months | On fluoresceine angiography if deemed necessary by the investigator : diffusion during late phases On angiography OCT : neovascular network visualisation |
| Anatomics parameters by oct | 6, 12, 24 and 36 months | Evaluation of anatomic parameters will be perfomed after 6,12, and 24 and 36 months of treatment with Eylea based on OCT parameters : On SD-OCT : Distance from CNV lesion to the fovea measured on the scan joining the fovea to the foveal edge of the mCNV Exudation assessed by presence of intraretinal cysts or subretinal fluid Central retinal thickness |
Countries
France
Outcome results
None listed